Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Prebet

Showing results (91-100 of 99) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 99 results.
Blood Advances|April 25, 2018
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohortMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Blood Advances|July 25, 2018
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohortMaximilian Stahl, Michelle DeVeaux, Theo de Witte, et al.
Haematologica|April 4, 2020
Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with <i>FLT3</i>-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationAli Bazarbachi, Gesine Bug, Frederic Baron, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 13, 2018
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective StudyMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
The Lancet. Haematology|November 12, 2022
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trialJustin M Watts, Maria R Baer, Jay Yang, et al.
Leukemia & Lymphoma|September 3, 2021
Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplantJan Philipp Bewersdorf, Andriy Derkach, Lohith Gowda, et al.
International Journal of Molecular Sciences|April 20, 2017
Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational StudyAntonio M Almeida, Thomas Prebet, Raphael Itzykson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2021
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021Daniel A Pollyea, Dale Bixby, Alexander Perl, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2019
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in OncologyMartin S Tallman, Eunice S Wang, Jessica K Altman, et al.
Pageof 10

Showing results (91-100 of 99) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 99 results.
Blood Advances|April 25, 2018
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohortMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Blood Advances|July 25, 2018
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohortMaximilian Stahl, Michelle DeVeaux, Theo de Witte, et al.
Haematologica|April 4, 2020
Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with <i>FLT3</i>-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationAli Bazarbachi, Gesine Bug, Frederic Baron, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 13, 2018
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective StudyMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
The Lancet. Haematology|November 12, 2022
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trialJustin M Watts, Maria R Baer, Jay Yang, et al.
Leukemia & Lymphoma|September 3, 2021
Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplantJan Philipp Bewersdorf, Andriy Derkach, Lohith Gowda, et al.
International Journal of Molecular Sciences|April 20, 2017
Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational StudyAntonio M Almeida, Thomas Prebet, Raphael Itzykson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2021
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021Daniel A Pollyea, Dale Bixby, Alexander Perl, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2019
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in OncologyMartin S Tallman, Eunice S Wang, Jessica K Altman, et al.
Pageof 10